How big is the Keytruda market?

The global Keytruda market size was estimated at USD 31.38 billion in 2025 and is expected to reach USD 32.72 billion in 2026.

What is the Keytruda market growth?

The global Keytruda market is expected to grow at a compound annual growth rate of -3.80% from 2026 to 2033 to reach USD 24.95 billion by 2033.

Which segment accounted for the largest Keytruda market share?

Based on application, the lung cancer segment dominated the Keytruda market with a revenue share of 26.91% in 2025. The strong market presence is driven by Keytruda’s established role as a first-line and adjuvant treatment for non-small cell lung cancer (NSCLC), supported by extensive clinical evidence demonstrating superior survival benefits over chemotherapy.

Who are the key players in the Keytruda market?

Merck & Co., Inc. dominates the Keytruda market, as it is the exclusive manufacturer and patent holder of the blockbuster PD-1 inhibitor.

What are the factors driving the Keytruda market?

The market is driven by its increasing adoption across multiple cancer indications. As a leading immune checkpoint inhibitor, Keytruda has demonstrated strong efficacy in treating non-small cell lung cancer, melanoma, head and neck cancers, and other malignancies, leading to broader regulatory approvals worldwide.